OAM
BPMC

Oberweis Asset Management’s Blueprint Medicines BPMC Stock Holding History

Oberweis Asset Management’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-72,500
Closed -$9.29M – 185
2025
Q2 		$9.29M Sell
72,500
-2,500
-3% -$260K 0.4% 90
2025
Q1 		$6.64M Hold
75,000
– – 0.33% 112
2024
Q4 		$6.54M Buy
+75,000
New +$6.87M 0.31% 118
2018
Q1 		– Sell
-6,700
Closed -$505K – 226
2017
Q4 		$505K Buy
6,700
+100
+2% +$7.04K 0.12% 162
2017
Q3 		$460K Hold
6,600
– – 0.13% 117
2017
Q2 		$334K Hold
6,600
– – 0.09% 121
2017
Q1 		$264K Buy
+6,600
New +$236K 0.08% 121

Other funds holding BPMC

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
VanEck Associates
VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Oberweis Asset Management's BPMC Position: Q3 2025 in Review

Oberweis Asset Management sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 72,500 shares — an estimated $9.29M sold.

Oberweis Asset Management first reported a position in BPMC in Q1 2017 and held it in 7 quarters. The position peaked at $9.29M in Q2 2025. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.

  • Oberweis Asset Management reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
  • Oberweis Asset Management sold 72,500 Blueprint Medicines shares in Q3 2025, an estimated $9.29M.
  • Oberweis Asset Management first reported a position in Blueprint Medicines in Q1 2017 and held it in 7 quarters.
  • Oberweis Asset Management's Blueprint Medicines position peaked at $9.29M in Q2 2025.
  • 5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.

Based on Oberweis Asset Management's 13F filing for Q3 2025, filed 17 Nov 2025.